Literature DB >> 8169857

Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments.

I A Paul1, G Nowak, R T Layer, P Popik, P Skolnick.   

Abstract

Chronic (14 day) but not acute (1 day) treatment of mice with clinically active antidepressants produces a significant (approximately 1.8-4.3 fold) reduction in the potency of glycine to inhibit [3H]-5,7-dichlorkynurenic acid (5,7-DCKA) binding to strychnine-insensitive glycine receptors in neocortical membranes. Moreover, these effects were not observed following chronic treatment with a variety of nonantidepressant drugs such as D-deprenyl, chlorpromazine, salbutamol, scopolamine and chlordiazepoxide. The time course and dose-response relationships for this effect were examined after treatment with two representative antidepressant drugs (imipramine and citalopram) and electriconvulsive shock (ECS). Increases in the IC50 of glycine to inhibit [3H]-5,7-DCKA binding were observed after treatment for 7 days with ECS, 10 days with citalopram and 14 days with imipramine, respectively, and were no longer apparent by the 10th day after cessation of treatment. These findings indicate that the antidepressant-induced reduction in the IC50 of glycine to inhibit [3H]-5,7-DCKA binding is: 1) a slowly developing, adaptive phenomenon; 2) remarkably persistent after cessation of treatment; and 3) a significantly better predictor of antidepressant activity (22 of 23 drugs) than either beta adrenoceptor down-regulation (15 of 23 drugs) or efficacy in the forced swim test (13 of 23 drugs) [P < .01 vs. each measure, Fisher's Exact Test]. The ability of antidepressants drawn from every principal therapeutic class to effect adaptive changes in the N-methyl-D-aspartate receptor complex is consistent with the hypothesis that this ligand-gated ion channel serves as a final common pathway of antidepressant action and indicates that glutamatergic pathways may be involved in the pathophysiology of depression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8169857

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 3.  Vagus nerve stimulation (VNS) for depression: what do we know now and what should be done next?

Authors:  Ziad Nahas; Carol Burns; Milton J Foust; Baron Short; Tal Herbsman; Mark S George
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

4.  NMDA receptors trigger neurosecretion of 5-HT within dorsal raphe nucleus of the rat in the absence of action potential firing.

Authors:  C P J de Kock; L N Cornelisse; N Burnashev; J C Lodder; A J Timmerman; J J Couey; H D Mansvelder; A B Brussaard
Journal:  J Physiol       Date:  2006-10-19       Impact factor: 5.182

Review 5.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

6.  Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study.

Authors:  P A Boyer; P Skolnick; L H Fossom
Journal:  J Mol Neurosci       Date:  1998-06       Impact factor: 3.444

Review 7.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

8.  N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents.

Authors:  Ovsanna Leyfer; Aubrey Carpenter; Donna Pincus
Journal:  Child Psychiatry Hum Dev       Date:  2019-04

9.  NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test.

Authors:  Mehdi Ghasemi; Laleh Montaser-Kouhsari; Hamed Shafaroodi; Behtash Ghazi Nezami; Farzad Ebrahimi; Ahmad Reza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2009-07-16       Impact factor: 4.530

Review 10.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.